Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
The deal gives the company access to a range of central nervous system disorder drugs
The deal gives J&J access to Intra-Cellular’s central nervous system disorder drugs, including antipsychotic medication Caplyta (lumateperone).
♦️The once-daily oral therapy is already approved by the US Food and Drug Administration (FDA) to treat adults with schizophrenia, and depressive episodes associated with bipolar I or II disorder as a monotherapy and adjunctive therapy with lithium or valproate.
♦️Schizophrenia and bipolar disorder affect approximately 2.4 million and 6.1 million adults in the US, respectively.
♦️A supplemental new drug application has also been submitted to the US regulator for the use Caplyta as an adjunctive treatment for major depressive disorder, which affects as estimated 21 million adults in the US, while additional late-stage trials of the drug in other mental health disorders are underway.
♦️Beyond Caplyta, the acquisition includes a phase 2 candidate being evaluated in generalised anxiety disorder and Alzheimer’s disease-related psychosis and agitation, as well as a clinical-stage pipeline that “further complements and strengthens” J&J’s current areas of focus.
♦️Jennifer Taubert, executive vice president, worldwide chairman, Innovative Medicine, J&J, said: “We are excited to welcome Intra-Cellular Therapies’ talented people and world-class expertise to J&J. Together, we have an opportunity to impact even more patients living with neuropsychiatric and neurodegenerative disorders, significantly advancing care and helping improve the lives of millions worldwide.”
♦️Under the terms of the agreement, which is expected to close later this year subject to applicable regulatory approvals, J&J will acquire all outstanding shares of Intra-Cellular Therapies for $132 per share in cash.
♦️Also commenting on the acquisition, Sharon Mates, chairman and chief executive officer of Intra-Cellular Therapies, said: “Caplyta’s success and the robust pipeline we have built demonstrates the passion and dedication of our… team, and we are proud of the hundreds of thousands of patients we have helped.
“J&J has a longstanding commitment to neuroscience, and we believe together, we can reach even more patients around the world.”
